Skip to Content

Healthcare Venture Capital and Private Equity

“Meeting Growth Objectives within an Evolving Regulatory and Economic Environment”


  • Examples of novel technologies VC firms are supporting that are focused on improving patient care and reducing healthcare costs.
  • Greatest challenges VC firms are facing in today’s regulatory and economic environment.
  • Exit options today for early-stage life science companies.
  • Attractive investment opportunities for private equity firms in the healthcare services sector (payor, provider, HCIT, etc.).
  • Impact of the current state of the financial markets on PE strategies. 
  • Attractive healthcare investment opportunities in markets outside the US.

Robert Schulz
General Partner
Health Enterprise Partners

Prior to co-founding HEP, Mr. Schulz was a General Partner of CB Health Ventures’ two funds, CB Healthcare Fund (1997) and CB Healthcare Fund II (2001). Mr. Schulz spent three years as the President and COO of Harris & Harris Group, Inc., a publicly traded venture capital fund. Investments include: Passport Health (recap by Primus), Emageon (NASDAQ: EMAG); acquired by AMICAS, CareMedic Systems, CorSolutions (acquired by Matria), Optimal Readings, SCIOinspire and ContinuumRx.

Mr. Schulz is a director of ContinuumRx, formerly Principle Pharmacy Group and SCIOinspire (HEP companies) and several CBHV portfolio companies including CareMedic Systems, Carefx Corporation, and Skylight Healthcare Systems. He was a director of CorSolutions Medical, and Passport Health Communications prior to their sale by CB Health Ventures.

Mr. Schulz received a Bachelors and Masters degree in Chemical Engineering from Massachusetts Institute of Technology (1979) and an MBA from Columbia University Graduate School of Business (1983).

David Bonita MD
Principal, Private Equity

David Bonita, M.D., is a Principal on the Private Equity team. Prior to joining Orbimed, Dr. Bonita worked as a corporate finance analyst in the healthcare investment banking groups of Morgan Stanley and UBS. He has also published scientific articles in peer reviewed journals based on signal transduction research performed at the Harvard Medical School. Dr. Bonita received his A.B. degree magna cum laude in Biological Sciences from Harvard University and his joint M.D./M.B.A. from Columbia University where he was elected to the Alpha Omega Alpha Medical Honor Society and Beta Gamma Sigma Business Honor Society.

Jonathan Korngold
Managing Director
General Atlantic

Jonathan Korngold is a Managing Director at General Atlantic, a global growth equity firm, where he has worked since 2001.  Mr. Korngold has worked in General Atlantic's London office and is now based in the firm's New York office, where he heads General Atlantic's global Healthcare sector. 

In his capacity as a Managing Director, Mr. Korngold has worked closely with many of the firm's public and private portfolio companies, many of which are in the healthcare services, healthcare technology, life sciences, transaction processing, and financial services areas, and he is currently a Board member of Emdeon.

Prior to joining General Atlantic, Mr. Korngold was a member of Goldman Sachs's Principal Investment Area and Mergers & Acquisitions groups in London and New York, respectively. Mr. Korngold received his M.B.A. from Harvard Business School and graduated with an A.B. in Economics with Honors from Harvard College. In addition, Mr. Korngold has spent extensive time in China, where he studied Mandarin Chinese at Peking University and worked in the U.S. Embassy's Foreign Commercial Service in Beijing.

Mr. Korngold is involved in a number of educational and non-profit organizations, including serving on the Boards of The Central Park Conservancy, The 92nd Street Y, and Kids In Distressed Situations (K.I.D.S.).

Andrew Paul
Managing General Partner
Enhanced Equity Funds

Mr. Paul is the Founder and Managing Partner of Enhanced Equity Funds (EEF). Mr. Paul has been actively engaged in private equity and venture capital investing for 28 years, primarily focused on healthcare services. Prior to EEF, Mr. Paul spent 16 years at Welsh Carson Anderson & Stowe (“WCAS”) where he was a Managing General Partner. After retiring from WCAS in 2000, Mr. Paul focused his energies on investing in small capitalization companies and in 2005, he co-founded EEF. He is the most senior member of EEF’s Investment Committee. Mr. Paul serves on the Board of Directors of Correctional Healthcare Companies, Guardian Healthcare, Aphena Pharma Solutions, NextCare, and MedTest. He received a Bachelor of Arts from Cornell University and an MBA from Harvard Business School. Mr. Paul is also the Founder and Chairman of the Board of Directors of Enhanced Capital Partners, Inc. and Chairman of its Investment Committees. Enhanced Capital is a diversified national asset management company that provides investment capital to small businesses that are traditionally underserved by conventional sources of financing.

Robert Seltzer
Care Capital LLC

Bob Seltzer joined Care Capital in 2005 and became a Partner in 2010. Prior to Care Capital, Mr. Seltzer was a management consultant with the Boston Consulting Group where he focused on the pharmaceutical industry, identifying and analyzing strategic opportunities in R&D. Previously, Mr. Seltzer performed financial analysis in GlaxoSmithKline's Deal Structuring Group, and he co-founded and was President of the technology company Trenza Corp.

Prior to his business career, Mr. Seltzer was an accomplished chess player, winning five US National titles for his age group and earning the title of Life National Master. Mr. Seltzer holds a B.S. in Molecular Biophysics and Biochemistry from Yale University, a Masters of Biotechnology from the University of Pennsylvania, and an MBA from The Wharton School, where he was a Palmer Scholar.